{"product_id":"vtvt-vrio-analysis","title":"vTv Therapeutics Inc. (VTVT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to vTv Therapeutics Inc. (VTVT)'s competitive edge! This focused VRIO analysis distills whether its key assets are truly Valuable, Rare, Inimitable, and Organized to deliver sustainable success. Scroll down immediately to see the definitive verdict on what truly drives this business's performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 1. Cadisegliatin (TTP399) Lead Asset Status\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at vTv Therapeutics Inc.'s main bet, Cadisegliatin (TTP399), and trying to figure out if it’s a real long-term winner. Honestly, the near-term value is tied directly to the success of the ongoing Phase 3 CATT1 trial. If that data lands well in the second half of 2026, this asset has the potential to be a game-changer for Type 1 Diabetes (T1D) patients.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Addressing a Major Unmet Need\u003c\/h3\u003e\n\u003cp\u003eThe core value proposition here is clear: Cadisegliatin is being developed as a potential first-in-class oral adjunctive therapy for T1D. Think about that - an oral pill to use alongside insulin. That addresses a massive, persistent unmet need in diabetes management. The company is putting its money where its mouth is; R\u0026amp;D expenses jumped to \u003cstrong\u003e$7.0 million\u003c\/strong\u003e in the third quarter of 2025, up significantly from \u003cstrong\u003e$3.2 million\u003c\/strong\u003e in Q3 2024, largely due to increased spending on this very program.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Novel Mechanism in Late-Stage Development\u003c\/h3\u003e\n\u003cp\u003eA novel, oral glucokinase activator (GKA) specifically for T1D is genuinely rare in late-stage clinical development right now. Most innovation in this space has focused on injectables or devices. vTv Therapeutics Inc. is pursuing a different, potentially simpler route for patients. This novelty in mechanism and delivery makes it rare, but rarity alone doesn't guarantee advantage; that depends on the next two factors.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Molecule Uniqueness and Patent Protection\u003c\/h3\u003e\n\u003cp\u003eThe specific molecule and the clinical data generated around it are unique to vTv Therapeutics Inc., making direct imitation very difficult. Furthermore, they've bolstered this with legal protection. A U.S. patent covering crystalline salt forms of Cadisegliatin was recently allowed, offering exclusivity expected to last out to \u003cstrong\u003e2041\u003c\/strong\u003e. That's a long runway, which is defintely a strong barrier to entry for competitors looking at the exact same chemical entity.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Execution and Funding\u003c\/h3\u003e\n\u003cp\u003eThe organization appears structured to push this asset forward. They recently closed an \u003cstrong\u003e$80 million\u003c\/strong\u003e private placement in September 2025 specifically to fund the CATT1 trial. As of September 30, 2025, their cash position stood at \u003cstrong\u003e$98.5 million\u003c\/strong\u003e, giving them the necessary runway to reach the expected topline data readout in the second half of 2026. They even hired a Chief Commercial Officer in March 2025 to start planning for a potential launch.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003epotential and contingent\u003c\/strong\u003e. It will only become sustained if the Phase 3 CATT1 trial is successful, demonstrating efficacy in reducing hypoglycemia events over the 26-week treatment period. The trial itself was streamlined in 2025, shortening the duration from 12 to 6 months to expedite data delivery.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of the VRIO assessment for this lead asset:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eSupporting Data\/Metric (2025 Fiscal Year)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh Potential\u003c\/td\u003e\n    \u003ctd\u003eOral adjunctive therapy for T1D; R\u0026amp;D spend rose to \u003cstrong\u003e$7.0 million\u003c\/strong\u003e in Q3 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003ePotential first-in-class oral GKA for T1D in late-stage development\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eCostly\/Difficult\u003c\/td\u003e\n    \u003ctd\u003eUnique molecule; Patent exclusivity expected through \u003cstrong\u003e2041\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eOrganized\u003c\/td\u003e\n    \u003ctd\u003eSecured \u003cstrong\u003e$80 million\u003c\/strong\u003e financing in Sep 2025; Cash balance \u003cstrong\u003e$98.5 million\u003c\/strong\u003e as of Sep 30, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained (Conditional)\u003c\/td\u003e\n    \u003ctd\u003eSuccess hinges on topline CATT1 data expected in H2 2026\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the binary risk: if the CATT1 trial fails to meet its primary endpoint - reducing Level 2 or Level 3 hypoglycemia - the entire value proposition collapses, regardless of the patent life. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 2. Composition of Matter Patent Protection\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides market exclusivity for specific crystalline forms of cadisegliatin expected through \u003cstrong\u003e2041\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Strong, patent-protected exclusivity for a late-stage asset is always rare. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very low; patent law makes direct imitation of the composition of matter nearly impossible. The patent application was directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The legal\/IP team successfully secured the allowance of this key U.S. patent from the United States Patent and Trademark Office (USPTO).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the patent remains valid and un-challenged. The ongoing Phase 3 CATT1 trial is expected to report topline data in the second half of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey milestones and financial context related to the asset's development:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposition of Matter Patent Term End\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003e2041\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCrystalline Forms of Cadisegliatin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Data Expectation\u003c\/td\u003e\n\u003ctd\u003eSecond Half of \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCATT1 Trial Topline Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClosed in September \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense (Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on the intellectual property and financial backing:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe USPTO issued a Notice of Allowance for the patent application in August \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company's cash position as of December 31, \u003cstrong\u003e2024\u003c\/strong\u003e, was \u003cstrong\u003e$36.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral \u0026amp; Administrative (G\u0026amp;A) expenses were \u003cstrong\u003e$3.7 million\u003c\/strong\u003e for the three months ended September 30, \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCadisegliatin is a novel, oral small molecule, liver-selective glucokinase activator.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 3. Phase 3 Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Demonstrates the ability to manage a complex, double-blind, randomized Phase 3 trial (CATT1) for T1D, supported by prior tolerability data in over 500 subjects with up to six months of treatment. The program has also been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; achieving randomization in a Phase 3 trial is a significant operational milestone for a company of this stage.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate; the specific trial design, including the use of 800 mg dose regimens, and the established investigator network are not instantly replicable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Operational readiness is demonstrated by successfully randomizing the first patient in August 2025. This execution is supported by a strengthened balance sheet following a $80 million private placement in September 2025, with cash reported at $98.5 million as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; this advantage is contingent upon successful trial completion and subsequent regulatory approval, with topline data from CATT1 expected in the second half of 2026.\u003c\/p\u003e\n\u003cp\u003eThe execution capability is detailed by the following CATT1 Phase 3 trial parameters:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eParameter\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Status Milestone\u003c\/td\u003e\n\u003ctd\u003eFirst Participant Randomized\u003c\/td\u003e\n\u003ctd\u003eAugust \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Duration (Amended)\u003c\/td\u003e\n\u003ctd\u003eTreatment Period\u003c\/td\u003e\n\u003ctd\u003e6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Sites\u003c\/td\u003e\n\u003ctd\u003eNumber of U.S. Sites\u003c\/td\u003e\n\u003ctd\u003eUp to 25 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Enrollment\u003c\/td\u003e\n\u003ctd\u003eApproximate Participants\u003c\/td\u003e\n\u003ctd\u003e150 participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Regimens Assessed\u003c\/td\u003e\n\u003ctd\u003eCadisegliatin vs. Placebo\u003c\/td\u003e\n\u003ctd\u003e800 mg once or twice daily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Data Readout\u003c\/td\u003e\n\u003ctd\u003eTopline Data\u003c\/td\u003e\n\u003ctd\u003eSecond half of 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial metrics related to R\u0026amp;D execution for the period include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expense for Q3 2025: $7.0 million.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expense for Q3 2024: $3.2 million.\u003c\/li\u003e\n\u003cli\u003eNet loss attributable to vTv shareholders for Q3 2025: $8.7 million.\u003c\/li\u003e\n\u003cli\u003eNet loss per basic share for Q3 2025: $1.08.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 4. Strengthened Balance Sheet and Funding Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The successful closing of an \u003cstrong\u003e$80 million\u003c\/strong\u003e private placement in September 2025 provides capital to fund the ongoing CATT1 Phase 3 trial and continued development, positioning the Company to report topline results in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; securing \u003cstrong\u003e$80 million\u003c\/strong\u003e in gross proceeds as a pre-revenue entity demonstrates significant, albeit not unique, investor conviction in the cadisegliatin program.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific terms, including the participation of the T1D Fund and existing investors, and the timing relative to the CATT1 trial randomization in August 2025, are not directly replicable by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management secured the financing, resulting in a material increase in liquidity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Proceeds\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months Cash Burn\u003c\/td\u003e\n\u003ctd\u003eAs of September 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalculated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eAs of September 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e4.7 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financing structure included specific components:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAggregate gross proceeds of approximately \u003cstrong\u003e$80 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSale of \u003cstrong\u003e682,018\u003c\/strong\u003e shares of Class A Common Stock and pre-funded warrants to purchase \u003cstrong\u003e4,561,714\u003c\/strong\u003e shares, with accompanying warrants to purchase an aggregate of \u003cstrong\u003e5,243,732\u003c\/strong\u003e shares.\u003c\/li\u003e\n\u003cli\u003ePurchase price per unit (share + warrant) was \u003cstrong\u003e$15.265\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePurchase price per unit (pre-funded warrant + warrant) was \u003cstrong\u003e$15.255\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe exercise price of the accompanying warrants is \u003cstrong\u003e$22.71\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eWarrants expire upon the earlier of the fifth anniversary of issuance or \u003cstrong\u003e90 days\u003c\/strong\u003e following the announcement of positive topline data from the CATT1 trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is the funding runway extending past the expected topline data readout in \u003cstrong\u003eH2 2026\u003c\/strong\u003e, calculated to be approximately \u003cstrong\u003e4.7 years\u003c\/strong\u003e based on the trailing twelve months cash burn of \u003cstrong\u003e$21 million\u003c\/strong\u003e as of September 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 5. Liver-Selective Glucokinase Activator (GKA) Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMechanism of action: Liver-selective activation of Glucokinase (GK) to improve glycemic control and reduce the risk of hypoglycemia. FDA Breakthrough Therapy designation granted in 2021.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLead program, Cadisegliatin (TTP399), is in a Phase 3 clinical trial (CATT1) as an adjunctive therapy to insulin for Type 1 Diabetes (T1D).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eU.S. patent covering crystalline salts and co-crystals of cadisegliatin allowed with exclusivity expected through 2041.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D expenses were $13.6 million for the year ended December 31, 2023, and $11.5 million for the year ended December 31, 2024. Cash position was $9.4 million as of December 31, 2023.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses (3 months ended Sep 30, 2024): $3.2 million.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses (3 months ended Sep 30, 2025): $7.0 million.\u003c\/li\u003e\n\u003cli\u003eCash Position (Sep 30, 2025): $98.5 million following an $80 million private placement in September 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdvancing through Phase 3 CATT1 trial, with topline data expected in the second half of 2026.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Stage\u003c\/td\u003e\n\u003ctd\u003ePhase 3 (CATT1)\u003c\/td\u003e\n\u003ctd\u003eEvaluating Cadisegliatin for T1D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Duration (Amended)\u003c\/td\u003e\n\u003ctd\u003e6 months\u003c\/td\u003e\n\u003ctd\u003eShortened from 12 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Topline Data\u003c\/td\u003e\n\u003ctd\u003eH2 2026\u003c\/td\u003e\n\u003ctd\u003eFrom CATT1 study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Enrollment\u003c\/td\u003e\n\u003ctd\u003eApproximately 150 patients\u003c\/td\u003e\n\u003ctd\u003eAt 20-25 sites in the U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint\u003c\/td\u003e\n\u003ctd\u003eNumber of level 2 and level 3 hypoglycemic events\u003c\/td\u003e\n\u003ctd\u003eCompared between cadisegliatin and placebo.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Exclusivity End\u003c\/td\u003e\n\u003ctd\u003e2041\u003c\/td\u003e\n\u003ctd\u003eFor crystalline salts and co-crystals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 6. Scientific Advisory Board (SAB) Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Access to international leaders in endocrinology and regulatory science to guide clinical strategy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe SAB provides strategic guidance for cadisegliatin, which is currently being investigated in \u003cstrong\u003ePhase 3\u003c\/strong\u003e clinical trials and has received \u003cstrong\u003eBreakthrough Therapy designation\u003c\/strong\u003e from the U.S. Food and Drug Administration. Cadisegliatin has shown good tolerance in over \u003cstrong\u003e500 subjects\u003c\/strong\u003e during trials lasting up to \u003cstrong\u003esix months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many companies have boards, but the caliber of the October 2025 appointments is key.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company announced the appointment of \u003cstrong\u003e4\u003c\/strong\u003e new members to its SAB on \u003cstrong\u003eOctober 9, 2025\u003c\/strong\u003e, enhancing the board's depth in diabetes care and clinical research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Low; recruiting top-tier, specialized Key Opinion Leaders takes time and reputation.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe board includes internationally recognized leaders from institutions such as Yale University, the University of Cambridge, and the University of Leuven, Belgium.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: The SAB is structured to advise on trial design and regulatory strategy for cadisegliatin.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe SAB's collective experience is leveraged for strategic guidance on clinical trial planning, study design, and regulatory strategy for the oral therapy, cadisegliatin. Topline data from the CATT1 Phase 3 trial is expected in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; reputation and relationships with top experts are sticky assets.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe expertise supports a program valued in the context of the company's market capitalization of \u003cstrong\u003e$158 million\u003c\/strong\u003e as of \u003cstrong\u003eOctober 2025\u003c\/strong\u003e, with the stock having surged over \u003cstrong\u003e60%\u003c\/strong\u003e year-to-date.\u003c\/p\u003e\n\u003cp\u003eThe SAB composition includes the following key figures:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMember\u003c\/td\u003e\n\u003ctd\u003ePrimary Expertise Area\u003c\/td\u003e\n\u003ctd\u003eAffiliation Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJohn Buse, MD, PhD\u003c\/td\u003e\n\u003ctd\u003eClinical Trial Design, Diabetes Outcomes\u003c\/td\u003e\n\u003ctd\u003eProfessor of Medicine at the University of North Carolina at Chapel Hill; former President of the American Diabetes Association\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlexander Fleming, MD\u003c\/td\u003e\n\u003ctd\u003eRegulatory Strategy\u003c\/td\u003e\n\u003ctd\u003eRecognized expert in regulatory strategy; former FDA role in therapeutic review of diabetes and other metabolic and endocrine disorders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlfonso Galderisi, MD, PhD\u003c\/td\u003e\n\u003ctd\u003ePediatric Endocrinology\u003c\/td\u003e\n\u003ctd\u003ePediatric endocrinologist and physician-scientist (Associate Professor) at Yale University\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMark Evans, MD\u003c\/td\u003e\n\u003ctd\u003eDiabetic Medicine, Hypoglycemia\u003c\/td\u003e\n\u003ctd\u003eProfessor of Diabetic Medicine at the University of Cambridge, U.K.; contributor to the Hypo-RESOLVE consortium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChantal Mathieu, MD, PhD\u003c\/td\u003e\n\u003ctd\u003eDiabetes Care and Guidelines\u003c\/td\u003e\n\u003ctd\u003eProfessor of Medicine at the University of Leuven, Belgium; global expert in diabetes care and guidelines (EASD, EUDF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKlara Klein, MD, PhD\u003c\/td\u003e\n\u003ctd\u003eT1D Therapeutics Investigation\u003c\/td\u003e\n\u003ctd\u003eAssistant Professor at the University of North Carolina at Chapel Hill; Principal Investigator for multiple vTv clinical trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial context related to development supported by SAB guidance includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch \u0026amp; Development (R\u0026amp;D) Expenses for the three months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$7.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Position as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$98.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss attributable to vTv shareholders for the three months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$8.7 million\u003c\/strong\u003e or \u003cstrong\u003e$1.08 per basic share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancing activity in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e: Successful closing of an \u003cstrong\u003e$80 million\u003c\/strong\u003e private placement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 7. Regulatory Navigation Success\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFDA placed clinical hold in \u003cstrong\u003eJuly 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eClinical hold was lifted on \u003cstrong\u003eMarch 18, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 3 CATT1 trial resumption planned for \u003cstrong\u003eQ2 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe hold was resolved after clarifying the chromatographic signal was an 'experimental artifact'.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ePrevious trials involved over \u003cstrong\u003e500 subjects\u003c\/strong\u003e treated for up to \u003cstrong\u003esix months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCATT1 trial duration is expected to be reduced from \u003cstrong\u003e12 months\u003c\/strong\u003e to \u003cstrong\u003esix months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOriginal primary endpoint: assessing level \u003cstrong\u003etwo and three hypoglycemia rates at six months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe specific data package used to resolve the hold is proprietary.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrengthened balance sheet.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement Financing (Sept 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTo fund CATT1 Phase 3 trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (3 months ended 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects higher spending on cadisegliatin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (3 months ended 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease primarily due to payroll and legal expenses.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eTopline results from CATT1 trial expected in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCadisegliatin has \u003cstrong\u003eBreakthrough Therapy designation\u003c\/strong\u003e from the FDA (granted in 2021).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 8. Oral Small Molecule Development Focus\n\u003c\/h2\u003e\n\u003cp\u003e\nThe focus on an oral small molecule for Type 1 Diabetes (T1D) adjunctive therapy positions the company within a market segment where patient preference strongly favors non-injectable options.\n\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\nDeveloping an oral pill for T1D adjunctive therapy is highly preferred by patients over injectables. The global Type 1 Diabetes Treatment Market was estimated at \u003cstrong\u003eUSD 34.87 billion\u003c\/strong\u003e in 2024 and is projected to reach \u003cstrong\u003eUSD 74.03 billion\u003c\/strong\u003e by 2034, exhibiting a compound annual growth rate (CAGR) of \u003cstrong\u003e7.82%\u003c\/strong\u003e between 2024 and 2034.\n\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\nWhile many small molecules exist, a successful oral T1D adjunctive therapy would be a market disruptor. The Oral Insulin Therapies Market is expected to grow at a \u003cstrong\u003e35.5% CAGR\u003c\/strong\u003e during the forecast period for 2025-2034.\n\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\nThe expertise in developing this specific class of small molecule is concentrated. The company's lead candidate, cadisegliatin, has a U.S. patent covering crystalline salts and co-crystals with exclusivity expected through \u003cstrong\u003e2041\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\nThe company explicitly states its focus is on developing oral, small molecule drug candidates. The company's cash position as of September 30, 2025, was \u003cstrong\u003e$98.5 million\u003c\/strong\u003e, following an \u003cstrong\u003e$80 million\u003c\/strong\u003e private placement in September 2025, intended to fund the ongoing Phase 3 trial.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2024 (Sep 30, 2024)\u003c\/th\u003e\n\u003cth\u003eQ3 2025 (Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003ePeriod End (Dec 31, 2023)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Shareholders (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\nTemporary; if a competitor launches a similar oral agent first, this advantage erodes. The Phase 3 CATT1 trial for cadisegliatin is expected to report topline results in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nFDA clinical hold on the cadisegliatin program was lifted in \u003cstrong\u003eMarch 2025\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nFirst patient randomized in the Phase 3 CATT1 trial in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nThe company reported a Quick Ratio of \u003cstrong\u003e9.69\u003c\/strong\u003e and a Current Ratio of \u003cstrong\u003e9.79\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003evTv Therapeutics Inc. (VTVT) - VRIO Analysis: 9. Strategic Investor Base Support\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Inclusion of specialized investors like the T1D Fund in the September 2025 financing validates the T1D market opportunity. The financing involved an \u003cstrong\u003e$80 million\u003c\/strong\u003e Private Placement in Public Equity (PIPE).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having a specialized fund as a key backer signals strong sector belief. The T1D Fund: A Breakthrough T1D Venture, LLC participated alongside existing investors Samsara BioCapital, L.P. and new investors Trails Edge Capital Partners and Invus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; securing investment from a niche, expert fund is relationship-driven. The financing closed on or around September 3, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The CEO, Paul Sekhri, Chairman, President and Chief Executive Officer, commented on the financing enabling continued advancement of cadisegliatin.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this provides short-term stability but doesn't guarantee long-term success. Topline data from the CATT1 trial is expected in the second half of 2026.\u003c\/p\u003e\n\u003cp\u003eThe September 2025 financing details are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal PIPE Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClass A Shares Sold\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e682,018\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-funded Warrants for Class A Shares\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4.56 million\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccompanying Warrants for Class A Stock\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.24 million\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchase Price per Unit (Stock + Warrant)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.265\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchase Price per Unit (Pre-funded Warrant + Warrant)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.255\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccompanying Warrants Exercise Price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$22.71\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe third quarter financial snapshot leading up to the financing closing is:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss attributable to vTv shareholders for the three months ended September 30, 2025: \u003cstrong\u003e$8.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss per basic share for Q3 2025: \u003cstrong\u003e$1.08\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch \u0026amp; Development (R\u0026amp;D) Expenses for Q3 2025: \u003cstrong\u003e$7.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral \u0026amp; Administrative (G\u0026amp;A) Expenses for Q3 2025: \u003cstrong\u003e$3.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompany's cash position as of September 30, 2025: \u003cstrong\u003e$98.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompany's cash position as of December 31, 2024: \u003cstrong\u003e$36.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe 13-week cash flow projection incorporating the Q3 \u003cstrong\u003e$8.7 million\u003c\/strong\u003e net loss and the \u003cstrong\u003e$80 million\u003c\/strong\u003e placement proceeds is required by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516279087253,"sku":"vtvt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vtvt-vrio-analysis.png?v=1740230341","url":"https:\/\/dcf-model.com\/products\/vtvt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}